In this renewal application, the Pediatric AIDS Clinical Trials Group Unit at the University of Miami School of Medicine, composed of a functionally integrated Perinatal/Pediatric Research Network of investigators from the Division of Pediatric Infectious Disease, Adolescent Medicine and Obstetrics, proposes to contribute significantly to the scientific agenda of the PACTG. We will continue to enroll large numbers of HIV-1 infected women, children, and adolescents into PACTG sponsored clinical trials. Approximately 150 patients will be enrolled during the first year of the next funding cycle into one or more (1) Primary therapy studies, (2) Opportunistic infection studies, (3) Perinatal intervention trials, (4) Vaccine trials, and (5) Long-term observational protocols. Finally, the Miami Unit will continue to maintain its excellent record in data management. This Network is led by Dr. Gwendolyn Scott (P.I., Dept. of Pediatrics) and Dr. Mary Jo O'Sullivan (Co-PI, Dept. of Obstetrics) both of whom are recognized nationally and internationally for their expertise in HIV infection and have an ongoing leadership role in the PACTG. Dr. Scott will be assisted in these efforts by Drs. Lawrence Friedman and Charles Mitchell who will have the responsibility of overseeing the enrollment of adolescents and children younger than 13 respectively. The PACTG Network will continue to contribute to the scientific agenda of the PACTG by developing new protocols, participating in scientific committees, and assisting in the expansion of the scientific endeavors of the PACTG in the developing world. The University of Miami has been funded by the Fogarty International Center for the last decade and presently has three Fogarty initiatives which provide research training for international fellows (from Brazil, the Dominican Republic, and Zambia) in Pediatric AIDS, Maternal and Child Health, and Medical Informatics. The strength of the Miami Perinatal Research Network relates to (1) the expertise of the faculty and their distinguished record in the conduct of clinical trials, (2) an extensive infrastructure of psychosocial and medical support which has facilitated the enrollment and retention of patients in clinical trials at our site, (3) an outstanding record in data management (4) excellent laboratory support from the PACTG Core Virology Laboratory and an ACTG certified immunology laboratory, (5) a large population of HIV-1 infected women, children, and adolescents, (6) outreach efforts that integrate with community programs, and (7) International collaborations for expansion of clinical trials.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01AI027560-17
Application #
6857079
Study Section
Special Emphasis Panel (ZAI1-PSS-A (J1))
Program Officer
Germuga, Donna E
Project Start
1988-09-30
Project End
2007-02-28
Budget Start
2005-03-01
Budget End
2006-02-28
Support Year
17
Fiscal Year
2005
Total Cost
$999,382
Indirect Cost
Name
University of Miami School of Medicine
Department
Pediatrics
Type
Schools of Medicine
DUNS #
052780918
City
Miami
State
FL
Country
United States
Zip Code
33146
Aweeka, F T; Hu, C; Huang, L et al. (2015) Alteration in cytochrome P450 3A4 activity as measured by a urine cortisol assay in HIV-1-infected pregnant women and relationship to antiretroviral pharmacokinetics. HIV Med 16:176-83
Weinberg, Adriana; Dickover, Ruth; Britto, Paula et al. (2008) Continuous improvement in the immune system of HIV-infected children on prolonged antiretroviral therapy. AIDS 22:2267-77
Read, J S; Best, B M; Stek, A M et al. (2008) Pharmacokinetics of new 625 mg nelfinavir formulation during pregnancy and postpartum. HIV Med 9:875-82
Mirochnick, Mark; Best, Brookie M; Stek, Alice M et al. (2008) Lopinavir exposure with an increased dose during pregnancy. J Acquir Immune Defic Syndr 49:485-91
Sharma, Tanvi S; Hughes, Jane; Murillo, Amarylis et al. (2008) CD8+ T-cell interleukin-7 receptor alpha expression as a potential indicator of disease status in HIV-infected children. PLoS One 3:e3986
McKinney Jr, Ross E; Rodman, John; Hu, Chengcheng et al. (2007) Long-term safety and efficacy of a once-daily regimen of emtricitabine, didanosine, and efavirenz in HIV-infected, therapy-naive children and adolescents: Pediatric AIDS Clinical Trials Group Protocol P1021. Pediatrics 120:e416-23
Stek, Alice M; Mirochnick, Mark; Capparelli, Edmund et al. (2006) Reduced lopinavir exposure during pregnancy. AIDS 20:1931-9
Tuomala, Ruth E; Shapiro, David E; Mofenson, Lynne M et al. (2002) Antiretroviral therapy during pregnancy and the risk of an adverse outcome. N Engl J Med 346:1863-70
Laufer, M; Scott, G B (2000) Medical management of HIV disease in children. Pediatr Clin North Am 47:127-53
Geffin, R B; Scott, G B; Melenwick, M et al. (1998) Association of antibody reactivity to ELDKWA, a glycoprotein 41 neutralization epitope, with disease progression in children perinatally infected with HIV type 1. AIDS Res Hum Retroviruses 14:579-90

Showing the most recent 10 out of 15 publications